Clinical trials of new drugs for Alzheimer disease

• Published in: Journal of biomedical science Vol. 27; no. 1; pp. 18 - 13
• Main Authors: Huang, Li-Kai, Chao, Shu-Ping, Hu, Chaur-Jong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2020; BioMed Central; BMC
• Subjects: Advertising executives; Alzheimer disease; Alzheimer's disease; Amyloidosis; Anti-Alzheimer's disease agents; Anti-amyloid; Anti-tau; Aspartate; Atrophy; Biomarkers; Brain; Cholinesterase; Cholinesterase inhibitors; Clinical trials; Clinical trials of drugs; Cognitive ability; Dementia; Dementia disorders; Disease control; Diseases; Drug therapy; Drugs; Glutamate receptors; Hypotheses; Immunotherapy; Inflammation; Magnetic resonance imaging; Medical research; Memory; Metabolism; N-methyl-D-aspartate; N-Methyl-D-aspartic acid receptors; Neurodegeneration; Neurodegenerative diseases; Neuroinflammation; Neuroprotection; Neurotransmitters; Pathogenesis; Peptides; Pharmaceutical industry; Product development; Psychological symptoms; Reason; Review; Signs and symptoms; Tau protein; Time; Trends; United States > US; Neuroprotection; Anti-tau; Alzheimer disease; Anti-amyloid; Neuroinflammation; Cognitive enhancement; Clinical trials of drugs

Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an anta...